Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Estrella Immunopharma, Inc. (ESLA) had Income from Continuous Operations of $-4.80M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-4.80M |
|
-- |
|
-- |
|
$4.80M |
|
$-4.80M |
|
-- |
|
$-4.80M |
|
$-4.80M |
|
$-4.80M |
|
|
Income from Continuous Operations |
$-4.80M |
$-4.80M |
|
$-4.80M |
|
$-4.80M |
|
$-4.80M |
|
37.10M |
|
37.10M |
|
$-0.13 |
|
$-0.13 |
|
| Balance Sheet Financials | |
$2.02M |
|
-- |
|
$1.50M |
|
$3.52M |
|
$13.36M |
|
-- |
|
-- |
|
$13.36M |
|
$-9.84M |
|
$-9.84M |
|
$-9.84M |
|
37.77M |
|
| Cash Flow Statement Financials | |
$-1.61M |
|
-- |
|
$2.32M |
|
$0.92M |
|
$1.63M |
|
$0.71M |
|
$0.47M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.15 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.61M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
48.81% |
|
48.81% |
|
-136.26% |
|
48.81% |
|
$-0.26 |
|
$-0.04 |
|
$-0.04 |
|